Navigation Links
Data suggest liver experts should take care when prescribing novel antiviral HCV drugs
Date:4/2/2011

Berlin, Germany, Saturday 02 April 2011: Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance is minimised.1,2,3,4,5,6

Several studies observed the rapid onset of HCV resistance in patients treated with NS3-protease, NS5b-polymerase and NS5a inhibitors. Although these direct anti-virals are effective in both treatment-naive HCV patients and those who've been previously unresponsive to current treatment options, the development of resistant viral variants may cause problems in the future. In fact, two studies found HCV strains resistant to novel antiviral compounds pre-existed in patients who had never previously been exposed to the new antiviral compounds. In these patients, the variants were selected out by treatment.

Professor Heiner Wedemeyer, EASL's Secretary General, said: "While the regulatory approval of these new treatments is a highly anticipated milestone in HCV therapy, these studies show that care must be taken in the prescription and use of the new compounds. What we want to avoid is a rapid spread of HCV resistance within the patient population, which could drastically lower the effectiveness of the new drugs."

The current standard of care for chronic HCV is the combination of pegylated interferon-alfa and ribavirin, but only 40-54% of patients infected with HCV genotype 1 achieve a sustained virological response (SVR).7,8 Novel antiviral therapeutics are much sought after to treat patients who don't respond to the current standard of care. As such, a large number of new drugs for HCV are at various stages of preclinical and clinical development.9

However, as each new copy of the HCV genome exhibits on average one nucleotide change per replication cycle, HCV's replication machinery allows the virus to quickly come up with mutations that render it resistant to antiviral drugs. This is a major concern for successful anti-HCV therapy.10

NS3 protease inhibitors block the function of the HCV NS3 protease, an enzyme essential for HCV's replication. NS5A replication complex inhibitors block the function of HCV nonstructural protein 5A, a multifunctional protein essential for HCV replication.10


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. CU-Boulder study suggests air quality regulations miss key pollutants
2. Models of eel cells suggest electrifying possibilities
3. Atomic-resolution views suggest function of enzyme that regulates light-detecting signals in eye
4. NJIT professors research suggests changes in underwater data communications
5. Seasonal affective disorder may be linked to genetic mutation, study suggests
6. Revised theory suggests carbon dioxide levels already in danger zone
7. Shrimp trawling may boost mercury in red snapper, study suggests
8. Discovery of new gene associated with diabetes risk suggests link with body clock
9. Purdue study suggests warmer temperatures could lead to a boom in corn pests
10. Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests
11. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... ... voice recognition biometrics market to grow at a CAGR of 19.36% ... present scenario and the growth prospects of the global voice recognition ... considers the revenue generated from the sales of voice recognition biometrics ...
(Date:1/19/2017)... CLARA, Calif. , Jan. 19, 2017 /PRNewswire/ ... company enhancing user experience and security for consumer ... of next-generation payment processing systems and cybersecurity solutions, ... more banks, enterprises and financial institutions worldwide to ... part of the end-to-end secure user authentication platforms ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... ... 16, 2017 , ... Avomeen & MichBio will be hosting a BioMixer next ... Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers are a ... to interact with peers, make new connections and talk bio biz. , Cost:, ...
(Date:2/16/2017)... 2017 Research and Markets has ... Markets" report to their offering. ... The ... parts, delivery plasmids, chassis organisms, synthetic cells, production systems), ... editing, bioinformatics and specialty media) and enabled technologies (biofuels, ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
Breaking Biology Technology: